Hims & Hers Health, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Andrew Dudum
- Full Time Employees
- 2,442
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- 2269 Chestnut Street San Francisco CA United States of America 94123
- IPO Date
- Sep 13, 2019
- CIK
- 0001773751
- Website
- hims.com
- Similar Companies
- Business
- Hims & Hers Health, Inc. operates a telehealth platform providing direct-to-consumer healthcare services and products primarily across the United States, the United Kingdom, and select European markets, with plans for further global expansion. The company offers a comprehensive range of core products and services including prescription medications, over-the-counter drugs, and personal care products under its consumer-facing brands Hims (targeting men) and Hers (targeting women). Key product categories encompass sexual health treatments such as erectile dysfunction medications and birth control; hair care products including hair loss treatments; mental health services including therapy and coaching; weight loss programs integrating medication; skincare products; and preventive health solutions. The platform connects customers with licensed healthcare providers who deliver personalized treatment plans through virtual consultations, often asynchronously, supported by ongoing clinical care and educational resources. Hims & Hers also operates vertically integrated pharmacy fulfillment facilities alongside partnerships with external pharmacies for prescription delivery. Founded in 2017 and headquartered in San Francisco, California, Hims & Hers has rapidly evolved from focusing initially on men's health and stigmatized conditions like erectile dysfunction to a broad telehealth ecosystem covering multiple specialties and wellness areas for both men and women. Recent major developments include the acquisition of YourBio Health, which brings advanced pain-free blood sampling technology to enhance diagnostic services, and the strategic acquisition of ZAVA, a leading European digital health platform, which expands Hims & Hers’ footprint into the UK, Germany, France, and Ireland with plans to further penetrate European markets. The company also announced a significant collaboration with Novo Nordisk to expand affordable access to obesity care, alongside launching AI-powered tools like MedMatch to personalize treatment plans using large-scale data analytics. Additionally, Hims & Hers initiated a $250 million share repurchase program in 2025 and planned a market entry into Canada timed with availability of generic weight loss medication semaglutide. Hims & Hers operates within the broader healthcare and biotechnology sectors and targets adult consumers seeking accessible, affordable, and stigma-free telehealth services and products. Its business model integrates telemedicine consultations, electronic medical records, cloud-based pharmacy fulfillment, and personalized healthcare technology. With over 2.4 million subscribers as of mid-2025, the company has scaled its operations nation-wide in the US and strategically expanded internationally through acquisitions and partnerships with major health systems like Ochsner, Mount Sinai, and Hartford Healthcare to enhance continuity of care that bridges digital and in-person services. The firm's continuous innovation and targeted market expansion position it as a growing leader in global digital health and wellness delivery.
Company News
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMS
Hims & Hers Health (NYSE: HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSS
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
HIMS & HERS HEALTH, INC. INVESTORS WITH LOSSES HAVE UNTIL NOVEMBER 2, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
Faruqi & Faruqi, LLP Urges Hims & Hers Health, Inc. (HIMS) Investors to Seek Counsel Before the November 2, 2026 Lead Plaintiff Deadline in the Securities Class Action
Portnoy Law Firm Announces Class Action on Behalf of Hims & Hers Health, Inc. Investors
Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Hims & Hers Health, Inc. - HIMS
Hims & Hers Health (HIMS) Investors with Substantial Losses Have Opportunity to Lead Hims & Hers Class Action Lawsuit Before November 2, 2026 Deadline
Kaplan Fox Announces a Securities Class Action Filed Against Hims & Hers Health, Inc. (HIMS) - Lead Plaintiff Deadline is November 2, 2026
Deadline Alert: Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
HIMS Class Action Reminder – Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Hims & Hers Health, Inc. Securities Class Action Lawsuit
Why Is Hims & Hers Health (HIMS) Down 7.7% Since Last Earnings Report?
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Kaplan Fox Urges Investors of Hims & Hers Health, Inc. (NYSE: HIMS) with Significant Losses to Seek a Leadership Role Before November 2, 2026
Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC
ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMS
Hims & Hers Health, Inc. (HIMS) Gains As Market Dips: What You Should Know
Hims & Hers Health (HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSS
Kaplan Fox Alerts Investors of Hims & Hers Health, Inc. (HIMS) with Significant Losses to a Securities Class Action Deadline on November 2, 2026